BP987

Desferrioxamine mesilate

British Pharmacopoeia (BP) Reference Standard

• Synonim(y): Deferoxamine mesylate salt, DFOM, Deferoxamine methanesulfonate salt, Desferrioxamine mesylate salt
• Wzór empiryczny (zapis Hilla): C₂₅H₄₈N₆O₈ · CH₄O₃S
• Numer CAS: 138-14-7
• Masa cząsteczkowa: 656.79
• UNSPSC Code: 41116107
• NACRES: NA.24
• MDL number: MFCD00058605

Właściwości

• grade: pharmaceutical primary standard
• agency: BP
• API family: desferrioxamine
• form: solid
• shelf life: limited shelf life, expiry date on the label
• manufacturer/tradename: BP
• application(s): pharmaceutical; pharmaceutical small molecule
• format: neat
• storage temp.: 2-8°C
• SMILES string: CS(O)(=O)=O.CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN
• InChI: 1S/C25H48N6O8.CH4O3S/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26;1-5(2,3)4/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34);1H3,(H,2,3,4)
• InChI key: IDDIJAWJANBQLJ-UHFFFAOYSA-N

Opis

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Desferrioxamine mesilate BP Reference standard, intended for use in laboratory tests only as specifically prescribed in the British Pharmacopoeia.

Also used in monographs such as:

Desferrioxamine Injection

Biochem/physiol Actions

An iron chelator used often in the studies of cell proliferation and apoptosis. Also reported to induce p53.

An iron chelator used often in the studies of cell proliferation and apoptosis. Has been shown to have anti-proliferative effects on vascular smooth muscle cells in vitro and in vivo and to arrest cells in the G1 phase. Also reported to induce p53. Induces apoptosis in HL-60 cells by chelating iron. After 48 hrs treatment with 1μM deferoxamine, DNA fragmentation was apparent. Cells treated with 0.1 μM deferoxamine for as little as 24 hours were committed to apoptosis; by 48 hrs nuclear collapse was observed. In some studies it has been shown to have antioxidant properties and to protect cells against H₂O₂-induced damage.

Packaging

Unit quantity: 30 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity please visit British Pharmacopoeia

Other Notes

Sales restrictions may apply.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 2
• flash_point_f: Not applicable
• flash_point_c: Not applicable